Takeda Pharmaceutical Company Limited (TAK)

17.47 +0.03 (+0.17%) At close: 4:00PM EST

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo 103-8668
Japan
81 3 3278 2306
http://www.takeda.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 47,495

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Christophe Weber	Pres, CEO & Representative Director	N/A	N/A	1966
Mr. Constantine Saroukos	CFO & Director	N/A	N/A	1971
Mr. Masato Iwasaki	Pres of Japan Pharma Bus. Unit & Director	N/A	N/A	1958
Dr. Andrew S. Plump	Pres of R&D and Director	N/A	N/A	1965
Dr. Seigo Izumo	Chair of Management Board	N/A	N/A	N/A
Mr. Haruhiko Hirate	Member of Management Board	N/A	N/A	1957
Salvatore Alesci	Member of Management Board and Head of R&D Global Science & Biomedical Policy	N/A	N/A	N/A
Mr. Iwaaki Taniguchi	Sr. VP of Corp. Fin. & Controlling Department	N/A	N/A	N/A
Mr. Christopher David O'Reilly	Global Head of Investor Relations & Global Fin.	N/A	N/A	N/A
Mr. Yoshihiro Nakagawa	Global Gen. Counsel	N/A	N/A	1960

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; and strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Corporate governance

Takeda Pharmaceutical Company Limited’s ISS governance QualityScore as of 3 December 2020 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.